Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.
Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups. Vergote I, et al. Among authors: kristensen gb. Int J Gynecol Cancer. 2010 Apr;20(3):476-8. doi: 10.1111/IGC.0b013e3181d3caa8. Int J Gynecol Cancer. 2010. PMID: 20375816 No abstract available.
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A. Pujade-Lauraine E, et al. J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24. J Clin Oncol. 2010. PMID: 20498395 Clinical Trial.
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. du Bois A, et al. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733132 Clinical Trial.
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J; Gynecological Cancer Intergroup. Rustin GJ, et al. Int J Gynecol Cancer. 2011 Feb;21(2):419-23. doi: 10.1097/IGC.0b013e3182070f17. Int J Gynecol Cancer. 2011. PMID: 21270624
First-line therapy in ovarian cancer trials.
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators. González Martín A, et al. Gynecol Oncol. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. Epub 2018 Nov 16. Gynecol Oncol. 2019. PMID: 30449719 Free PMC article. Clinical Trial.
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. Monk BJ, et al. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. doi: 10.1200/JCO.20.01164. Epub 2020 Aug 21. J Clin Oncol. 2020. PMID: 32822286 Free PMC article. Clinical Trial.
241 results